Nuvolase Inc. Release: PinPointe™ FootLaser™ Surpasses 100,000 Treatments for Onychomycosis

CHICO, Calif.--(BUSINESS WIRE)--NuvoLase Inc. announced today more then 100,000 procedures have now been performed with the PinPointe FootLaser worldwide, more than many of the other light-based options combined. The PinPointe FootLaser was the first light-based device to receive FDA clearance to treat onychomycosis (commonly known as nail fungus), and remains one of the only devices on the market today with documented clinically proven efficacy. The PinPointe FootLaser has been found to be an effective alternative to oral medications, which can be risky for the patient. The PinPointe FootLaser has been cleared by the FDA for the temporary improvement in the appearance of clear nail in patients with onychomycosis.